QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Dear Quest readers, Queen Elizabeth II referred to 1992 as an “annus horriblis,” Latin for a horrible year. To paraphrase the Queen, 2020 has not been a year on which the world shall look back with “undiluted pleasure.” Rather, 2020…
For the first time since 2012, the American Cancer Society (ACS) updated its guidelines for diet and physical activity, emphasizing individual choices that could reduce cancer risks. The guidelines are based on the latest available evidence. The ACS said that…
A study in Japan found that men who frequently ate mushrooms were less likely to be diagnosed with prostate cancer. A number of laboratories studies have suggested that mushrooms have a preventative effect on a number of cancers, including prostate…
Patients with metastatic castration-resistant prostate cancer (mCRPC) usually have limited response to immunotherapy. However, a Phase II trial found that an immunotherapy drug benefitted certain patients with this type of prostate cancer. The patients had a specific type of immune…
The 2020 American Urological Association (AUA) conference was held virtually June 27-28, 2020. Dr. Catalona shared his expertise and opinions as a featured speaker and was honored with the association’s most prestigious award. Dr. Catalona Argues that Biopsies are Still…
by Betsy Haberl In 2015, Chicago artist Chris Newman was diagnosed with prostate cancer. This summer, he is five years out from his surgery with Dr. Catalona and celebrating seeing one of his sculptures on display in downtown Chicago. For…
by William J. Catalona, M.D. Many hospitals and surgeons are committed to robotic surgery technology. In this regard, it has been claimed that 85% of the thousands of radical prostatectomies performed each year are now performed robotically. However, the FDA…
Earlier this year, the national media reported on two studies that examined the impact of lengthening PSA screening intervals based on a patient’s PSA value. The studies sought to determine if patients who had low PSA values when they are…
Family History of Breast Cancer is a Risk Factor for Prostate Cancer An analysis of 18 studies involving more than 17 million people found that a history of breast cancer in first-degree relatives was associated with an 18% increased risk…
In May, the U.S. Food and Drug Administration (FDA) approved two PARP inhibitors for men with certain genetic mutations and metastatic castration-resistant prostate cancer (mCRPC). The two drugs are olaparib (brand name Lynparza) and rucaparib (brand name Rubraca). Both of…
